Obata Shota, Hidaka Sumi, Yamano Mizuki, Yanai Mitsuru, Ishioka Kunihiro, Kobayashi Shuzo
Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Japan.
Department of Pathology, Sapporo Tokushukai Hospital, Japan.
Clin Kidney J. 2021 Sep 28;15(2):357-359. doi: 10.1093/ckj/sfab181. eCollection 2022 Feb.
Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.
接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗已证明在预防2019冠状病毒病（COVID-19）方面具有高效性且安全性良好，然而也有报道称COVID-19疫苗可能会增加免疫介导疾病的发生。我们在此报告一例接种用于COVID-19的mRNA疫苗BNT162b2（辉瑞/生物新技术公司）后发生髓过氧化物酶抗中性粒细胞胞浆抗体（ANCA）相关血管炎的病例。尽管疫苗与ANCA相关血管炎之间的因果关系尚不确定，但环境和遗传因素可能为血管炎的发展奠定了基础，而疫苗可能引发了多米诺效应。
